Skip to main content

Advertisement

SpringerLink
Log in

Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease—a consensus statement of the European Society of Endocrine Surgeons (ESES)

  • Review Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Purpose

This “consensus statement” aims to summarise the current evidence-based knowledge as to “timing” and planning the “extent“ of thyroid surgery in terms of an optimal balance between the prevention of thyroid malignancy (involving metastasis) and the risks associated with more extended surgery (permanent hypoparathyroidism, permanent paralysis of the recurrent laryngeal nerve). Surgery “in time” is influenced by genetic findings and age. Basal (and stimulated) calcitonin levels may individualise the timing and extent of surgery.

Materials and methods

The review of English-language studies addressing the management of REarranged during Transfection proto-oncogene mutation carriers including the time, extent of thyroid surgery and results. Evidence is mostly obtained from well-designed, non-experimental descriptive investigations, such as comparative, correlation and case–control studies (level III) with a grading of recommendation B, or from expert committee reports or opinions and/or the clinical experience of respected authorities (level IV) with a grading of recommendation C, respectively.

Results

“Risk level D” includes multiple endocrine neoplasia 2B cases. Thyroidectomy is recommended within the first year of life, preferably as soon as possible, due to the very early transformation of C cell hyperplasia to more aggressive tumours. Calcitonin levels may be less helpful. In patients with codon 634 mutations (risk level C), thyroidectomy between ages 2 and 4 years has been proposed based upon evidence of age-dependent and codon-specific progression of early medullary thyroid cancer. In “risk level B” (codons 609, 611, 618, 620, 630 and 804), tandem mutation (804–778) patients should undergo thyroidectomy before the age of 6 years. “Risk level A” includes patients with mutations in codons 321, 515, 533, 600, 603, 606, 635, 649, 666, 768, 776, 790, 791, 804 (single mutation), 833, 844, 861, 891 or 912. Surgery may be postponed until the age of 10 years.

However, postponing surgery and avoiding central (level VI) neck dissection in patients with risk levels A to C are only justified in families with a less aggressive MTC history and in combination with the results of basal (and calcium- or pentagastrin-stimulated) serum calcitonin levels. The moment of transition from C cell hyperplasia to MTC seems to occur when calcitonin levels rise. In patients with normal basal and stimulated calcitonin levels, the chance of micro-MTC increases significantly.

Conclusions

Hereditary C cell disease acts as a model to apply the results of bedside genetic testing, age and calcitonin levels (genotype–age–calcitonin-concept) for the individual timing of thyroid surgery and its extent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dralle H, Musholt TJ, Schabram J, Steinmuller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kussmann J, Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ, Muhlenberg R, Schober O, Rimmele H, Machens A (2013) German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg 398(3):347–375. doi:10.1007/s00423-013-1057-6

    Article  PubMed  Google Scholar 

  2. Pacini F, Castagna MG, Brilli L, Pentheroudakis G (2010) Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v214–219. doi:10.1093/annonc/mdq190

    Article  PubMed  Google Scholar 

  3. British Thyroid Association RCoP (2007) Guidelines for the management of thyroid cancer. http://www.british-thyroid-association.org/news/Docs/Thyroid_cancer_guidelines_2007.pdf

  4. Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783. doi:10.1097/MPA.0b013e3181ebb4f0

    Article  PubMed Central  PubMed  Google Scholar 

  5. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ (2010) Medullary carcinoma. J Natl Compr Canc Netw 8(5):512–530

    CAS  PubMed  Google Scholar 

  6. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA Jr (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6):565–612. doi:10.1089/thy.2008.0403

    Article  PubMed  Google Scholar 

  7. Machens A, Dralle H (2009) Prophylactic thyroidectomy in RET carriers at risk for hereditary medullary thyroid cancer. Thyroid 19(6):551–554. doi:10.1089/thy.2009.0144

    Article  PubMed  Google Scholar 

  8. Ball DW (2009) American Thyroid Association guidelines for management of medullary thyroid cancer: an adult endocrinology perspective. Thyroid 19(6):547–550. doi:10.1089/thy.2009.0147

    Article  PubMed  Google Scholar 

  9. Brauckhoff M, Gimm O (2009) Extrathyroidal manifestations of multiple endocrine neoplasia type 2. Thyroid 19(6):555–557. doi:10.1089/thy.2009.0151

    Article  PubMed  Google Scholar 

  10. Waguespack SG (2009) A perspective from pediatric endocrinology on the hereditary medullary thyroid carcinoma syndromes. Thyroid 19(6):543–546. doi:10.1089/thy.2009.0127

    Article  PubMed  Google Scholar 

  11. Daumerie C, Maiter D, Gruson D (2013) Serum calcitonin estimation in medullary thyroid cancer: basal or stimulated levels? Thyroid Res 6 Suppl 1:S4. doi:10.1186/1756-6614-6-S1-S4

  12. Fugazzola L, De Leo S, Perrino M (2013) The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association. Thyroid Res 6 Suppl 1:S8. doi:10.1186/1756-6614-6-S1-S8

  13. Jarzab B, Szpak-Ulczok S, Wloch J, Czarniecka A, Krajewska J (2013) Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers—the role of Ct serum level. Thyroid Res 6 Suppl 1:S9. doi:10.1186/1756-6614-6-S1-S9

  14. Elisei R et al (2012) 2012 European Thyroid Association, guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J 1:216–231

    Article  Google Scholar 

  15. Maier RV (2006) What the surgeon of tomorrow needs to know about evidence-based surgery. Arch Surg 141(3):317–323. doi:10.1001/archsurg.141.3.317

    Article  PubMed  Google Scholar 

  16. Holzer S, Reiners C, Mann K, Bamberg M, Rothmund M, Dudeck J, Stewart AK, Hundahl SA (2000) Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer 89(1):192–201. doi:10.1002/1097-0142(20000701)89:1<192::AID-CNCR26>3.0.CO;2-7

    Article  CAS  PubMed  Google Scholar 

  17. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S (2000) Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89(1):202–217. doi:10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A

    Article  CAS  PubMed  Google Scholar 

  18. Valle LA, Kloos RT (2011) The prevalence of occult medullary thyroid carcinoma at autopsy. J Clin Endocrinol Metab 96(1):E109–113. doi:10.1210/jc.2010-0959

    Article  CAS  PubMed  Google Scholar 

  19. Daniels GH (2011) Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid 21(11):1199–1207. doi:10.1089/thy.2010.0297

    Article  CAS  PubMed  Google Scholar 

  20. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E, Conte-Devolx B (1997) Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 82(2):338–341

    Article  CAS  PubMed  Google Scholar 

  21. Ozgen AG, Hamulu F, Bayraktar F, Yilmaz C, Tuzun M, Yetkin E, Tuncyurek M, Kabalak T (1999) Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 9(6):579–582

    Article  CAS  PubMed  Google Scholar 

  22. Pacini F, Fontanelli M, Fugazzola L, Elisei R, Romei C, Di Coscio G, Miccoli P, Pinchera A (1994) Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 78(4):826–829

    CAS  PubMed  Google Scholar 

  23. Papi G, Corsello SM, Cioni K, Pizzini AM, Corrado S, Carapezzi C, Fadda G, Baldini A, Carani C, Pontecorvi A, Roti E (2006) Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: a multicenter study. J Endocrinol Invest 29(5):427–437

    CAS  PubMed  Google Scholar 

  24. Rieu M, Lame MC, Richard A, Lissak B, Sambort B, Vuong-Ngoc P, Berrod JL, Fombeur JP (1995) Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol (Oxf) 42(5):453–460

    Article  CAS  Google Scholar 

  25. Biddinger P, Mukunda, R. (ed) (1993) Distribution of C cells in the normal and diseased thyroid gland. Pathology Annual 1:205-229; Virginia

    Google Scholar 

  26. Perry A, Molberg K, Albores-Saavedra J (1996) Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 77(4):750–756. doi:10.1002/(SICI)1097-0142(19960215)77:4<750::AID-CNCR22>3.0.CO;2-Z

    Article  CAS  PubMed  Google Scholar 

  27. Rosai J (ed) (1992) Tumors of the thyroid gland. In: Atlas of tumor pathology. Armed Forces Institute of Pathology, Washington DC

  28. Albores-Saavedra JA, Krueger JE (2001) C-cell hyperplasia and medullary thyroid microcarcinoma. Endocr Pathol 12(4):365–377

    Article  CAS  PubMed  Google Scholar 

  29. LiVolsi VA (1997) C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 82(1):39–41

    Article  CAS  PubMed  Google Scholar 

  30. Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Haas OA, Vierhapper H, Niederle B (2001) Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 25(10):1245–1251

    Article  CAS  PubMed  Google Scholar 

  31. Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Vierhapper H, Haas OA, Niederle B (1998) C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. Am J Surg Pathol 22(6):722–728

    Article  CAS  PubMed  Google Scholar 

  32. Kaserer K, Scheuba C, Neuhold N, Weinhausel A, Vierhapper H, Niederle B (2002) Recommendations for reporting C cell pathology of the thyroid. Wien Klin Wochenschr 114(7):274–278

    CAS  PubMed  Google Scholar 

  33. Iwashita T, Kato M, Murakami H, Asai N, Ishiguro Y, Ito S, Iwata Y, Kawai K, Asai M, Kurokawa K, Kajita H, Takahashi M (1999) Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma. Oncogene 18(26):3919–3922. doi:10.1038/sj.onc.1202742

    Article  CAS  PubMed  Google Scholar 

  34. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93(3):682–687. doi:10.1210/jc.2007-1714

    Article  CAS  PubMed  Google Scholar 

  35. Bugalho MJ, Domingues R, Santos JR, Catarino AL, Sobrinho L (2007) Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141(1):90–95. doi:10.1016/j.surg.2006.03.025

    Article  PubMed  Google Scholar 

  36. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92(12):4725–4729. doi:10.1210/jc.2007-1005

    Article  CAS  PubMed  Google Scholar 

  37. Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA, Ponder BA (1995) Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 43(1):123–127

    Article  CAS  Google Scholar 

  38. Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti P, Viola D, Biagini A, Basolo F, Ugolini C, Materazzi G, Pinchera A, Vitti P, Elisei R (2011) RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) 74(2):241–247. doi:10.1111/j.1365-2265.2010.03900.x

    Article  CAS  Google Scholar 

  39. Schuffenecker I, Ginet N, Goldgar D, Eng C, Chambe B, Boneu A, Houdent C, Pallo D, Schlumberger M, Thivolet C, Lenoir GM (1997) Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d’Etude des Tumeurs a Calcitonine. Am J Hum Genet 60(1):233–237

    CAS  PubMed Central  PubMed  Google Scholar 

  40. Wiench M, Wygoda Z, Gubala E, Wloch J, Lisowska K, Krassowski J, Scieglinska D, Fiszer-Kierzkowska A, Lange D, Kula D, Zeman M, Roskosz J, Kukulska A, Krawczyk Z, Jarzab B (2001) Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 19(5):1374–1380

    CAS  PubMed  Google Scholar 

  41. Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmayer C, Haas OA, Niederle B (2009) Sporadic hypercalcitoninemia: clinical and therapeutic consequences. Endocr Relat Cancer 16(1):243–253. doi:10.1677/ERC-08-0059

    Article  CAS  PubMed  Google Scholar 

  42. Wolfe HJ, Melvin KE, Cervi-Skinner SJ, Saadi AA, Juliar JF, Jackson CE, Tashjian AH Jr (1973) C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 289(9):437–441. doi:10.1056/NEJM197308302890901

    Article  CAS  PubMed  Google Scholar 

  43. McDermott MB, Swanson PE, Wick MR (1995) Immunostains for collagen type IV discriminate between C-cell hyperplasia and microscopic medullary carcinoma in multiple endocrine neoplasia, type 2a. Hum Pathol 26(12):1308–1312

    Article  CAS  PubMed  Google Scholar 

  44. Wells SA Jr, Pacini F, Robinson BG, Santoro M (2013) Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab 98(8):3149–3164. doi:10.1210/jc.2013-1204

    Article  CAS  PubMed  Google Scholar 

  45. Machens A, Lorenz K, Sekulla C, Hoppner W, Frank-Raue K, Raue F, Dralle H (2013) Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol 168(3):307–314. doi:10.1530/EJE-12-0919

    Article  CAS  PubMed  Google Scholar 

  46. Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ et al (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331(13):828–835. doi:10.1056/NEJM199409293311302

    Article  CAS  PubMed  Google Scholar 

  47. Machens A, Dralle H (2007) Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 31(5):957–968. doi:10.1007/s00268-006-0769-y

    Article  PubMed  Google Scholar 

  48. Wells SA Jr, Chi DD, Toshima K, Dehner LP, Coffin CM, Dowton SB, Ivanovich JL, DeBenedetti MK, Dilley WG, Moley JF et al (1994) Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220(3):237–247, discussion 247–250

    Article  PubMed  Google Scholar 

  49. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, Marsh DJ, Robinson BG, Frank-Raue K, Raue F, Xue F, Noll WW, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskjold M, Komminoth P, Hendy GN, Mulligan LM et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276(19):1575–1579

    Article  CAS  PubMed  Google Scholar 

  50. Raue F, Frank-Raue K (2012) Genotype–phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo) 67 Suppl 1:69–75

    Google Scholar 

  51. Waguespack SG, Rich TA, Perrier ND, Jimenez C, Cote GJ (2011) Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol 7(10):596–607. doi:10.1038/nrendo.2011.139

    Article  CAS  PubMed  Google Scholar 

  52. Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L, Chabre O, Boneu A, Caron J, Houdent C, Modigliani E, Rohmer V, Schlumberger M, Eng C, Guillausseau PJ, Lenoir GM (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D’etude des Tumeurs a Calcitonine. J Clin Endocrinol Metab 83(2):487–491

    CAS  PubMed  Google Scholar 

  53. Scholten A, Schreinemakers JM, Pieterman CR, Valk GD, Vriens MR, Borel Rinkes IH (2011) Evolution of surgical treatment of primary hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. Endocr Pract 17(1):7–15. doi:10.4158/EP10050.OR

    Article  PubMed  Google Scholar 

  54. Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C, Brauckhoff K, Thanh PN, Dralle H (2004) Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg 28(12):1305–1311. doi:10.1007/s00268-004-7637-4

    Article  PubMed  Google Scholar 

  55. Brauckhoff M, Machens A, Lorenz K, Bjoro T, Varhaug JE, Dralle H (2013) Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective. Ann Surg. doi:10.1097/SLA.0b013e3182a6f43a

    Google Scholar 

  56. Brauckhoff M, Machens A, Hess S, Lorenz K, Gimm O, Brauckhoff K, Sekulla C, Dralle H (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144(6):1044–1050. doi:10.1016/j.surg.2008.08.028, discussion 1050–1043

    Article  PubMed  Google Scholar 

  57. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658–5671

    Article  CAS  PubMed  Google Scholar 

  58. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349(16):1517–1525. doi:10.1056/NEJMoa012915

    Article  CAS  PubMed  Google Scholar 

  59. Machens A, Holzhausen HJ, Thanh PN, Dralle H (2003) Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations. Surgery 134(3):425–431

    Article  PubMed  Google Scholar 

  60. Schreinemakers JM, Vriens MR, Valk GD, de Groot JW, Plukker JT, Bax K, Hamming JF, van der Luijt RB, Aronson DC, Borel Rinkes IH (2010) Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study. World J Surg 34(4):852–860. doi:10.1007/s00268-009-0370-2

    Article  PubMed Central  PubMed  Google Scholar 

  61. Shepet K, Alhefdhi A, Lai N, Mazeh H, Sippel R, Chen H (2013) Hereditary medullary thyroid cancer: age-appropriate thyroidectomy improves disease-free survival. Ann Surg Oncol 20(5):1451–1455. doi:10.1245/s10434-012-2757-9

    Article  PubMed Central  PubMed  Google Scholar 

  62. Toledo SP, Lourenco DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE (2009) Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 64(7):699–706. doi:10.1590/S1807-59322009000700015

    Article  Google Scholar 

  63. Kratzsch J, Petzold A, Raue F, Reinhardt W, Brocker-Preuss M, Gorges R, Mann K, Karges W, Morgenthaler N, Luster M, Reiners C, Thiery J, Dralle H, Fuhrer D (2011) Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem 57(3):467–474. doi:10.1373/clinchem.2010.151688

    Article  CAS  PubMed  Google Scholar 

  64. Machens A, Haedecke J, Holzhausen HJ, Thomusch O, Schneyer U, Dralle H (2000) Differential diagnosis of calcitonin-secreting neuroendocrine carcinoma of the foregut by pentagastrin stimulation. Langenbecks Arch Surg 385(6):398–401

    Article  CAS  PubMed  Google Scholar 

  65. Bieglmayer C, Scheuba C, Niederle B, Flores J, Vierhapper H (2002) Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wien Klin Wochenschr 114(7):267–273

    CAS  PubMed  Google Scholar 

  66. Bieglmayer C, Vierhapper H, Dudczak R, Niederle B (2007) Measurement of calcitonin by immunoassay analyzers. Clin Chem Lab Med 45(5):662–666. doi:10.1515/CCLM.2007.124

    Article  CAS  PubMed  Google Scholar 

  67. Basuyau JP, Mallet E, Leroy M, Brunelle P (2004) Reference intervals for serum calcitonin in men, women, and children. Clin Chem 50(10):1828–1830. doi:10.1373/clinchem.2003.026963

    Article  CAS  PubMed  Google Scholar 

  68. Verga U, Morpurgo PS, Vaghi I, Radetti G, Beck-Peccoz P (2006) Normal range of calcitonin in children measured by a chemiluminescent two-site immunometric assay. Horm Res 66(1):17–20. doi:10.1159/000092848

    Article  CAS  PubMed  Google Scholar 

  69. Pina G, Dubois S, Murat A, Berger N, Niccoli P, Peix JL, Cohen R, Guillausseau C, Charrie A, Chabre O, Cornu C, Borson-Chazot F, Rohmer V (2013) Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test? Clin Endocrinol (Oxf) 78(3):358–364. doi:10.1111/cen.12001

    Article  CAS  Google Scholar 

  70. Colombo C, Verga U, Mian C, Ferrero S, Perrino M, Vicentini L, Dazzi D, Opocher G, Pelizzo MR, Beck-Peccoz P, Fugazzola L (2012) Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab 97(3):905–913. doi:10.1210/jc.2011-2033

    Article  CAS  PubMed  Google Scholar 

  71. Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2655–2663. doi:10.1210/jc.2009-2368

    Article  CAS  PubMed  Google Scholar 

  72. Scheuba C, Kaserer K, Weinhausl A, Pandev R, Kaider A, Passler C, Prager G, Vierhapper H, Haas OA, Niederle B (1999) Is medullary thyroid cancer predictable? A prospective study of 86 patients with abnormal pentagastrin tests. Surgery 126(6):1089–1095, discussion 1096

    Article  CAS  PubMed  Google Scholar 

  73. Machens A, Lorenz K, Dralle H (2009) Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg 250(2):305–310. doi:10.1097/SLA.0b013e3181ae333f

    Article  PubMed  Google Scholar 

  74. Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E, Agate L, Cappagli V, Miccoli P, Berti P, Faviana P, Ugolini C, Basolo F, Vitti P, Pinchera A (2012) The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clin Endocrinol Metab 97(2):426–435. doi:10.1210/jc.2011-2046

    Article  CAS  PubMed  Google Scholar 

  75. Scheuba C, Kaserer K, Bieglmayer C, Asari R, Riss P, Drosten R, Niederle B (2007) Medullary thyroid microcarcinoma recommendations for treatment—a single-center experience. Surgery 142 (6):1003–1010; discussion 1010 e1001-1003. doi:10.1016/j.surg.2007.09.016

    Google Scholar 

  76. Lau GS, Lang BH, Lo CY, Tso A, Garcia-Barcelo MM, Tam PK, Lam KS (2009) Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing. Hong Kong Med J 15(5):326–331

    PubMed  Google Scholar 

  77. Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL, Borson-Chazot F, Schvartz C, Tabarin A, Chabre O, Chabrier G, Caron P, Rodien P, Schlumberger M, Baudin E (2011) Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d’Etude des Tumeurs Endocrines. J Clin Endocrinol Metab 96(3):E509–518. doi:10.1210/jc.2010-1234

    Article  CAS  PubMed  Google Scholar 

  78. Raval MV, Sturgeon C, Bentrem DJ, Elaraj DM, Stewart AK, Winchester DJ, Ko CY, Reynolds M (2010) Influence of lymph node metastases on survival in pediatric medullary thyroid cancer. J Pediatr Surg 45(10):1947–1954. doi:10.1016/j.jpedsurg.2010.06.013

    Article  PubMed  Google Scholar 

  79. de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf) 65(6):729–736. doi:10.1111/j.1365-2265.2006.02659.x

    Article  Google Scholar 

  80. Morris LF, Waguespack SG, Edeiken-Monroe BS, Lee JE, Rich TA, Ying AK, Warneke CL, Evans DB, Perrier ND, Grubbs EG (2013) Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening. Ann Surg Oncol 20(1):53–59. doi:10.1245/s10434-012-2589-7

    Article  PubMed Central  PubMed  Google Scholar 

  81. Alevizaki M (2013) Management of hyperparathyroidism (PHP) in MEN2 syndromes in Europe. Thyroid Res 6 Suppl 1:S10. doi:10.1186/1756-6614-6-S1-S10

  82. Dralle H. MA, Bracukhoff M. (2012) Syndromic medullary thyroid carcinoma: MEN 2A and MEN 2B. Surgery of the thyroid and parathyroid glands 2nd edition. Philadelphia, PA, Elsevier, Saunders

  83. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Hoppner W, Raue F (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155(2):229–236. doi:10.1530/eje.1.02216

    Article  CAS  PubMed  Google Scholar 

  84. Dralle H, Gimm O, Simon D, Frank-Raue K, Gortz G, Niederle B, Wahl RA, Koch B, Walgenbach S, Hampel R, Ritter MM, Spelsberg F, Heiss A, Hinze R, Hoppner W (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22(7):744–750, discussion 750–741

    Article  CAS  PubMed  Google Scholar 

  85. Gonzalez-Sanchez C, Franch-Arcas G, Gomez-Alonso A (2013) Morbidity following thyroid surgery: does surgeon volume matter? Langenbecks Arch Surg 398(3):419–422. doi:10.1007/s00423-012-1027-4

    Article  PubMed  Google Scholar 

  86. Stavrakis AI, Ituarte PH, Ko CY, Yeh MW (2007) Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 142(6):887–899. doi:10.1016/j.surg.2007.09.003, discussion 887–899

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Section of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University, Währinger Gürtel 18-20, Vienna, 1090, Austria

    Bruno Niederle

  2. Endocrine Surgery, La Timone University Hospital, Marseille, 13005, France

    Frédéric Sebag

  3. Department of Surgery, Haukeland University Hospital, Bergen, 5021, Norway

    Michael Brauckhoff

Authors
  1. Bruno Niederle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frédéric Sebag
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Brauckhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno Niederle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Niederle, B., Sebag, F. & Brauckhoff, M. Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease—a consensus statement of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 399, 185–197 (2014). https://doi.org/10.1007/s00423-013-1139-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-013-1139-5

Keywords

Search

Navigation